key: cord-0864085-x1nj4c1j authors: Soin, Arvinder S.; Choudhary, Narendra S.; Yadav, Sanjay K.; Saigal, Sanjiv; Saraf, Neeraj; Rastogi, Amit; Bhangui, Prashant; Srinivasan, Thiagarajan; Mohan, Neelam; Saha, Sujeet K.; Gupta, Ankur; Chaudhary, Rohan J.; Yadav, Kamal; Dhampalwar, Swapnil; Govil, Deepak; Gupta, Nikunj; Vohra, Vijay title: Restructuring Living Donor Liver Transplantation at a High Volume Center During the COVID-19 Pandemic date: 2020-10-08 journal: J Clin Exp Hepatol DOI: 10.1016/j.jceh.2020.09.009 sha: 9f6ae99e44637e290190276d4457a10b494712c4 doc_id: 864085 cord_uid: x1nj4c1j BACKGROUND: Coronavirus disease 2019 (COVID-19) pandemic has led to deferral of elective transplants and pro-active pre-transplant testing of donor/recipient. The impact of these on living donor liver transplantation (LDLT) activity and outcome is not known. We performed LDLT only for sick or advanced hepatocellular carcinoma (HCC) patients in this period, with special COVID protocols. METHODS: Patients undergoing LDLT counseling, evaluation and transplant in the period March to June 2020 (group A) under COVID-19 restrictions and special protocols were included. LDLT activity and outcomes among these patients was compared to those in the same period in 2019 (group B). RESULTS: In the period March 15-June 10, we performed 39 and 23 (59%) LDLTs in 2019 and 2020 respectively. The adult patients with cirrhosis in-group A (n=20) had significantly higher MELD score, 19.8±7.0 versus 16.1±5.6 in-group B (n=36), p=0.034. Early recipient mortality was similar in 2019 (2/39) and 2020 (2/23). One out of 23 post-transplant recipients, 3/71 recipients and donors during evaluation, and 8/125 health care workers (HCWs) developed COVID-19, all of whom recovered uneventfully. CONCLUSION: LDLT activity substantially reduced during the COVID era. The incidence and outcome of COVID-19 among the waiting or transplanted patients and HCWs was similar to the general population. The outcome after LDLT in the COVID era was similar to non-COVID times. These data suggest that LDLT may be extended to more stable patients with strict protocols. Coronavirus disease 2019 (COVID-19) caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has a substantial risk of morbidity and mortality. 1 As of June 18, 2020, more than 8. 5 infection in many, who may transmit infection without coming to attention. 2 Various societies have suggested guidelines to defer hospital visits and LT in stable patients. [3] [4] [5] While there has been a decline of 30-80% in the deceased donor liver transplant activity in various countries, 6-10 the impact of the COVID-19 pandemic on LDLT has not been described. We describe our experience of LDLT in time of COVID-19 and compare the transplant activity during a similar non-COVID time period in 2019. Ours is a hub and spoke liver transplant system where around 240 transplants are performed annually, with around 200 at the main hub (Medanta, Gurugram) and the rest elsewhere, in 6 other centers. The effects of the COVID-19 pandemic on LDLT activity were studied at our center in the period March -June, 2020 in the context of COVID protocols and restrictions on transplant activity, and compared with the corresponding period in 2019. Outcomes after initial LDLT counseling, evaluation, and after LDLT were compared between the two periods. Specific hospital-based and LDLT related COVID protocols were followed during this period: Hospital-based state-guided protocols 11-13 a) Our tertiary care hospital demarcated its East and West wings separated by a 30- All staff on the ward, offices and outpatients wore N95 masks, followed hand hygiene and physical distancing norms. All staff changed disposable gowns and gloves and after every patient contact in all areas. The and HCWs were also noted. Data is shown as number, percentage, mean±standard deviation (parametric data). One of the LDLT recipients was diagnosed with asymptomatic COVID-19 on post-op day 15. He was tested as one of his attendants was found to have COVID-19. It was decided to maintain Tacrolimus level of 4-6 ng/l along with standard dose of mycophenolate and tapering doses of steroids. The recipient remained asymptomatic. The COVID-19 RT-PCR was repeated weekly and found to be negative on post-op day 29. Two prospective LT recipients and one prospective donor tested positive in preoperative COVID PCR testing. One of these prospective recipients had negative PCR one week before, but turned out to be positive one day prior to LT and LT was postponed. All these 3 (out of 71 tested) had been found to be positive on protocol testing during transplant evaluation, and none had symptoms at the time of testing. The two recipients are waiting for transplant once their report (2 sets one week apart) become negative for COVID19, whereas the donor has been rejected for donation for 6 weeks with at least 2 negative tests 1 week apart. ELITA/ELTR COVID-19 registry has reported 16% mortality in liver transplant recipients due to COVID-19. 21 The results suggest that mortality in liver transplant recipients might be higher in older recipients (> 60 year, 22%) than in younger J o u r n a l P r e -p r o o f patients (< 60 year, 0%) and could be worse in patients with longer time since transplantation (18% in those transplant done more than 2 year ago versus 5% in those who were transplanted within last 2 years). 21 We also refrained from minimal access donor hepatectomy to avoid inadvertent escape of CO 2 aerosols through or around ports during such surgery. 24, 25 Our in-hospital testing and PPE protocols for LT staff were very strict. There were several reasons for this cautious approach: the risk of fomite and person-person transmission 2 in the hospital setting with huge load of complex ICU patients, the risk of transmission from asymptomatic infected persons, 13 a vulnerable patient population who were sick with liver disease or immunosuppressed, the risk of prolonged viral shedding by immunosuppressed patients, 26 Efforts in resource planning, strict infection control, optimal recipient selection and screening of the donor and recipient are keys to maintaining safe LDLT activity and its careful extension to more stable patients. Transplant centers however, must remain open to readapting their practices as the pandemic evolves. Any conflicts of interest: none for any author Copyright assignment: In consideration of the Indian National Association for the Study of the Liver ("INASL") taking action to review and edit my submission, including possible re-design of figures and tables, and any other supplemental tables, illustration or other information submitted, herewith ("Article"), the undersigned Author, hereby transfers, conveys, and assigns all rights, titles and interests therein, including any and all copyrights to the INASL, however the Author will be always mentioned as such. As an exception to this rule, the Author acknowledges that the INASL will appear as the author when she/he participates in writing the Clinical Practice Guidelines. The Author will in this context be mentioned in a footnote as being a contributor. By signing this form I agree to INASL using any illustration (images or parts thereof) from the Article on the cover of the Journal of Clinical and Experimental Hepatology, on the INASL and Journal websites, and in any marketing material. In addition to reproduction in conventional printed and electronic (including online systems) forms, in all media (whether known or developed hereinafter), worldwide, in all languages, the Article will be stored electronically and the archived articles will be made available in electronic services. Assignment of copyright signifies agreement to the INASL making arrangements to include the Article in bundling of articles, document delivery services, CD-ROMS and electronic databases, etc. worldwide. In the light of the above, I acknowledge that to the extent permitted by applicable law any exploitation or other use (including translations, reprints, etc.) of the Article or of parts of it, either by myself or by a third party, is subject to the INASL's prior written consent. Should the INASL not publish the Article, the INASL agrees to release its rights therein. Authorship Responsibility: I, the undersigned Author, on behalf of all other Authors, certify that all Authors have participated sufficiently in the intellectual content, the analysis of data, if applicable, and the writing of the Article, and production of illustrations, to take public responsibility for it. I further certify that the Article contains no libellous or other unlawful statements and does not contain any materials that violate any personal or proprietary rights of any third party. I have obtained written permission from copyright owners for any excerpts from copyrighted works that are included and have credited the sources in my Article. I have reviewed the final version of the Article, believe it represents valid work, and approve it for publication. As an Author of this Article, I certify that none of the material in the Article has been published previously, is included in another manuscript or is currently under consideration for publication elsewhere. I also certify that this Article has not been accepted for publication elsewhere, nor have I assigned any right or interest in the manuscript to any third party (including employers, principals or governmental bodies). Moreover, should the INASL request data, upon which the Article is based, I shall produce it. a) The Authors who have taken part in this study declared that they do not have anything to disclose regarding funding or conflict of interest with respect to this manuscript b) The Authors who have taken part in this study do not have a relationship with the manufacturers of the drugs involved either in the past or present and did not receive funding from the manufacturers to carry out their research. The Authors received support from ….. c) The Authors who have taken part in this study have declared a relationship with the manufacturers of the drugs involved. d) The Authors have declared that they received funding from the drug companies involved in order to carry out their research in this manuscript. e) The Authors who have taken part in this study have declared a relationship with the manufacturers of the device/materials involved. f) The Authors have declared that they received funding from the manufacturers of the device/materials involved in order to carry out their research in this manuscript. Clinical Characteristics of Coronavirus Disease 2019 in China Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-CoV-1 Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID-19 Pandemic: AASLD Expert Panel Consensus Statement. Hepatol Baltim Md Liver transplantation and COVID-19 (Coronavirus) infection: guidelines of the liver transplant Society of India (LTSI) Care of patients with liver disease during the COVID-19 pandemic: EASL-ESCMID position paper Early Experience With COVID-19 and Solid Organ Transplantation at a US High-volume Transplant Center Early impact of COVID-19 on transplant center practices and policies in the United States Liver transplantation in the era of COVID-19 Strategies for Liver Transplantation during the SARS CoV-2 Outbreak Preliminary Experience from a Single Center in France The impact of the COVID-19 outbreak on liver transplantation programs in Northern Italy Correlation of Chest CT and RT-PCR Testing in Coronavirus Disease 2019 (COVID-19) in China: A Report of 1014 Cases Diagnosis of the Coronavirus disease (COVID-19): rRT-PCR or CT? Characteristics of and Important Lessons From the COVID-19) Outbreak in China: Summary of a Report of Cases From the Chinese Center for Disease Control and Prevention Covid-19: risk factors for severe disease and death COVID-19 in long-term liver transplant patients: preliminary experience from an Italian transplant centre in Lombardy COVID-19 in liver transplant recipients: preliminary data from the ELITA/ELTR registry The Lancet null. COVID-19: protecting health-care workers Society of Robotic Surgery Review: Recommendations Regarding the Risk of COVID-19 Transmission During Minimally Invasive Surgery SAGES and EAES recommendations for minimally invasive surgery during COVID-19 pandemic COVID-19: Thoughts and comments from a tertiary liver transplant center in France Living donor liver transplants for sick recipients during COVID-19 pandemic